Balanced news tone
News Sentiment
ARDX sentiment intelligence
Ardelyx Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
63 relevant articles
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+0.2% over one week, -7.2% over four weeks, trend inactive, and near fair-value range.
Lobbying Update: $500,000 of ARDELYX INC. lobbying was just disclosed
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
82/100 classification
One-week reaction
0.2%
Price digesting
Trend fit
Trend inactive
-7.2% over four weeks
Fair value
-8.0%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
42
Negative
6
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants
Ardelyx (ARDX) director Onaiza Cadoret-Manier was granted 26,455 restricted stock units (RSUs) and stock options for 39,715 shares on June 16, 2026, as part of the company's Non-Employee Director Compensation Program. Following these grants, her direct holdings in common stock to
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 19:39
- Source
- Stock Titan
simplywall.st
Direct company coverage
Ardelyx (ARDX) Stock Could Be 65% Undervalued As Growth Hopes Face Reassessment
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
ARDX (NASDAQ) insider sales: 125,000 shares notice; Raab 10b5-1 trades listed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Market source
Direct company coverage
Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Market source
MarketBeat
Direct company coverage
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
- Tone
- Positive 58/100
- Event
- Earnings
- Published
- 04 Jun 2026 12:04
- Source
- MarketBeat
Market source
Direct company coverage
Should You Buy Ardelyx (ARDX)?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
This Insider Has Just Sold Shares In Ardelyx
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- simplywall.st
MT Newswires
Direct company coverage
Ardelyx Insider Sold Shares Worth $261,612, According to a Recent SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 20:09
- Source
- MT Newswires
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's Changed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 May 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Ardelyx: Low Price, But High Implied Valuation (NASDAQ:ARDX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Seeking Alpha
Market source
Direct company coverage
Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 May 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 02 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is Ardelyx (ARDX) Offering Value After Recent Share Price Swings And DCF Estimate Gap
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Is Ardelyx (ARDX) Pricing Reflecting Its DCF Upside After Recent Share Price Swings
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Apr 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Apr 2026 07:00
- Source
- Market source
The Motley Fool
Direct company coverage
Ardelyx President and CEO Sells 41,000 Shares for $243,000
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Apr 2026 07:00
- Source
- The Motley Fool
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Stock Titan
Direct company coverage
Millions of women suffer IBS-C in silence; LPGA and Ardelyx team up
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Stock Titan
simplywall.st
Direct company coverage
Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jan 2026 08:00
- Source
- simplywall.st
scanx.trade
Direct company coverage
Zydus Lifesciences in talks to acquire US biopharma firm Ardelyx, may raise ₹5,000 crore via QIP
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 19 Jan 2026 08:00
- Source
- scanx.trade
Stocktwits
Direct company coverage
Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside — Says Constipation Drug ‘Stole The Show’ With 2026 Guidance
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 09 Jan 2026 08:00
- Source
- Stocktwits
Stocktwits
Direct company coverage
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jan 2026 17:01
- Source
- Stocktwits
simplywall.st
Direct company coverage
Ardelyx, Inc.'s (NASDAQ:ARDX) Path To Profitability
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Dec 2025 08:00
- Source
- simplywall.st